These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38781960)

  • 1. Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.
    Montalban-Bravo G; Thongon N; Rodriguez-Sevilla JJ; Ma F; Ganan-Gomez I; Yang H; Kim YJ; Adema V; Wildeman B; Tanaka T; Darbaniyan F; Al-Atrash G; Dwyer K; Loghavi S; Kanagal-Shamanna R; Song X; Zhang J; Takahashi K; Kantarjian H; Garcia-Manero G; Colla S
    Cell Rep Med; 2024 Jun; 5(6):101585. PubMed ID: 38781960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in
    Montalban-Bravo G; Ma F; Thongon N; Yang H; Gomez IG; Rodriguez-Sevilla JJ; Adema V; Wildeman B; Lockyer P; Kim YJ; Tanaka T; Darbaniyan F; Pancholy S; Zhang G; Al-Atrash G; Dwyer K; Takahashi K; Garcia-Manero G; Kantarjian H; Colla S
    bioRxiv; 2023 Apr; ():. PubMed ID: 37066354
    [No Abstract]   [Full Text] [Related]  

  • 3. Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia.
    Hammond D; Montalban-Bravo G
    Curr Hematol Malig Rep; 2021 Oct; 16(5):405-417. PubMed ID: 34499330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.
    Berg JL; Perfler B; Hatzl S; Mayer MC; Wurm S; Uhl B; Reinisch A; Klymiuk I; Tierling S; Pregartner G; Bachmaier G; Berghold A; Geissler K; Pichler M; Hoefler G; Strobl H; Wölfler A; Sill H; Zebisch A
    Clin Epigenetics; 2021 Jan; 13(1):1. PubMed ID: 33407852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia.
    Saliba AN; Litzow MR; Gangat N; Al-Kali A; Foran JM; Hogan WJ; Palmer JM; Mangaonkar AA; Tefferi A; Patnaik MM
    Am J Hematol; 2021 Nov; 96(11):E433-E436. PubMed ID: 34428328
    [No Abstract]   [Full Text] [Related]  

  • 6. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
    Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
    Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML.
    Sevin M; Debeurme F; Laplane L; Badel S; Morabito M; Newman HL; Torres-Martin M; Yang Q; Badaoui B; Wagner-Ballon O; Saada V; Sélimoglu-Buet D; Kraus-Berthier L; Banquet S; Derreal A; Fenaux P; Itzykson R; Braun T; Etienne G; Berthon C; Thépot S; Kepp O; Kroemer G; Padron E; Figueroa ME; Droin N; Solary E
    Blood; 2021 Jun; 137(24):3390-3402. PubMed ID: 33690800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients.
    Geissler K; Jäger E; Barna A; Gurbisz M; Graf T; Graf E; Nösslinger T; Pfeilstöcker M; Tüchler H; Sliwa T; Keil F; Geissler C; Heibl S; Thaler J; Machherndl-Spandl S; Zach O; Weltermann A; Bettelheim P; Stauder R; Zebisch A; Sill H; Schwarzinger I; Schneeweiss B; Öhler L; Ulsperger E; Kusec R; Germing U; Sperr WR; Knöbl P; Jäger U; Hörmann G; Valent P
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32344757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
    Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
    Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
    Teh TC; Nguyen NY; Moujalled DM; Segal D; Pomilio G; Rijal S; Jabbour A; Cummins K; Lackovic K; Blombery P; Thompson E; Ekert PG; Lessene G; Glaser SP; Huang DCS; Roberts AW; Guthridge MA; Wei AH
    Leukemia; 2018 Feb; 32(2):303-312. PubMed ID: 28751770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
    Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A
    Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis targeted therapies in acute myeloid leukemia: an update.
    Ball S; Borthakur G
    Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
    [No Abstract]   [Full Text] [Related]  

  • 13. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
    Ten Hacken E; Valentin R; Regis FFD; Sun J; Yin S; Werner L; Deng J; Gruber M; Wong J; Zheng M; Gill AL; Seiler M; Smith P; Thomas M; Buonamici S; Ghia EM; Kim E; Rassenti LZ; Burger JA; Kipps TJ; Meyerson ML; Bachireddy P; Wang L; Reed R; Neuberg D; Carrasco RD; Brooks AN; Letai A; Davids MS; Wu CJ
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
    Bazinet A; Darbaniyan F; Kadia TM; Venugopal S; Kanagal-Shamanna R; DiNardo CD; Borthakur G; Jabbour EJ; Daver NG; Pemmaraju N; Konopleva MY; Ravandi F; Sasaki K; Chien KS; Hammond D; Pierce SA; Kantarjian HM; Garcia-Manero G; Montalban-Bravo G
    Cancer; 2023 Feb; 129(4):560-568. PubMed ID: 36458426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
    Short NJ; Venugopal S; Qiao W; Kadia TM; Ravandi F; Macaron W; Dinardo CD; Daver N; Konopleva M; Borthakur G; Shpall EJ; Popat U; Champlin RE; Mehta R; Al-Atrash G; Oran B; Jabbour E; Garcia-Manero G; Issa GC; Montalban-Bravo G; Yilmaz M; Maiti A; Kantarjian H
    J Hematol Oncol; 2022 Jan; 15(1):12. PubMed ID: 35093134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs for the treatment of chronic myelomonocytic leukemia.
    Ramos Perez J; Montalban-Bravo G
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):515-529. PubMed ID: 33280448
    [No Abstract]   [Full Text] [Related]  

  • 17. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
    Alfonso A; Montalban-Bravo G; Takahashi K; Jabbour EJ; Kadia T; Ravandi F; Cortes J; Estrov Z; Borthakur G; Pemmaraju N; Konopleva M; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
    Am J Hematol; 2017 Jul; 92(7):599-606. PubMed ID: 28370097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
    Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
    Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
    Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477.
    Mallick DJ; Soderquist RS; Bates D; Eastman A
    Cell Death Dis; 2019 Feb; 10(3):185. PubMed ID: 30796196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.